Enrichment of BTK Leu528Trp mutations in patients with CLL on zanubrutinib: potential for pirtobrutinib cross-resistance

The covalent Bruton’s tyrosine kinase inhibitors (BTKis) are highly effective for the treatment of chronic lymphocytic leukemia (CLL). The dominant resistance mechanism observed with the BTKi ibrutinib is the development of BTK Cys481 codon mutations. Whether a similar resistance mutation profile ex...

Descripción completa

Detalles Bibliográficos
Autores principales: Blombery, Piers, Thompson, Ella R., Lew, Thomas E., Tiong, Ing Soo, Bennett, Rory, Cheah, Chan Y., Lewis, Katharine Louise, Handunnetti, Sasanka M., Tang, Chloe Pek Sang, Roberts, Andrew, Seymour, John F., Tam, Constantine S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2022
Materias:
Stimulus Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9647719/
https://www.ncbi.nlm.nih.gov/pubmed/35901282
http://dx.doi.org/10.1182/bloodadvances.2022008325

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9647719/
https://www.ncbi.nlm.nih.gov/pubmed/35901282
http://dx.doi.org/10.1182/bloodadvances.2022008325

Ejemplares similares